Evidence map›Paper›PMID 41304744›Full record

ReviewPharmaceutics2025

Research Progress on Nasal Delivery of siRNA Nanocarrier Systems for the Treatment of Neurodegenerative Diseases.

Qingqing Huang, Wei Wu, Yinghai Liu, Weiqing Li, Xin Chen, Sixun Yu, Gu Gong, Haifeng Shu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Qingqing HuangDepartment of Neurosurgery, The General Hospital of Western Theater Command, College of Medicine, Southwest Jiaotong University, Chengdu 610083, China.
Wei WuDepartment of Anesthesiology, The General Hospital of Western Theater Command, Chengdu 610083, China.
Yinghai LiuDepartment of Anesthesiology, The General Hospital of Western Theater Command, Chengdu 610083, China.
Weiqing LiDepartment of Anesthesiology, The General Hospital of Western Theater Command, Chengdu 610083, China.
Xin ChenDepartment of Neurosurgery, The General Hospital of Western Theater Command, College of Medicine, Southwest Jiaotong University, Chengdu 610083, China.
Sixun YuDepartment of Neurosurgery, The General Hospital of Western Theater Command, College of Medicine, Southwest Jiaotong University, Chengdu 610083, China.
Gu GongDepartment of Anesthesiology, The General Hospital of Western Theater Command, Chengdu 610083, China.
Haifeng ShuDepartment of Neurosurgery, The General Hospital of Western Theater Command, College of Medicine, Southwest Jiaotong University, Chengdu 610083, China.ORCID 0000-0002-0193-1881

Funding

Hospital-level Talent Nurturing Program NOSichuan Tianfu Qingcheng Plan Project No.1867the Clinical Independent Innovation Project of the General Hospital of Western Theater Command grant no. 2024-YGLC-B12
6 · The paper itself

Abstract

The treatment of central nervous system (CNS) diseases faces huge challenges, mainly due to the blood-brain barrier (BBB) restricting drug delivery, which leads to many potential treatment methods being unable to effectively reach the target area. In recent years, nasal administration has received extensive attention as a non-invasive drug delivery route because of its anatomical connection with the brain, enabling direct delivery to brain tissue. In particular, the siRNA delivery system based on nanocarriers has shown great promise in the treatment of CNS diseases due to its unique advantages in targeting gene silencing. This article reviews the latest research progress on nasal administration of siRNA nanocarriers, with a focus on the design strategies, administration mechanisms, in vivo and in vitro effects, and safety evaluations of different nanocarriers. The aim is to provide a systematic theoretical basis and future research directions for the application of siRNA nasal administration in the treatment of CNS diseases (see the abstract of the picture).

Indexed as

blood-brain barriercentral nervous system diseasesdendritic polymersnanocarriersnasal deliverynon-invasive deliverysiRNA

Identifiers

PMID41304744
PMCPMC12655281

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.